BiotechTube
Home/Pipeline/Athebody® DARPins for Targeted Radioligands (with POINT Biopharma)

Athebody® DARPins for Targeted Radioligands (with POINT Biopharma)

Oncology (Solid Tumors)

Pre-clinicalActive Partnership

Key Facts

Indication
Oncology (Solid Tumors)
Phase
Pre-clinical
Status
Active Partnership
Company
Athebio

About Athebio

Athebio is a privately held biotech company founded in 2019, leveraging its Athebody® DARPin platform to empower drug developers with a versatile, 'plug & play' scaffold for creating superior targeted therapeutics. The company's mission is to explore and unleash the therapeutic potential of repeat proteins, offering partners a technology characterized by high specificity, solubility, stability, and ease of manufacturing. Athebio's business model is centered on strategic partnerships and technology transfer, as evidenced by its collaboration with POINT Biopharma to develop targeted radioligands.

View full company profile

Therapeutic Areas

OncologyGenetic Diseases

Other Oncology (Solid Tumors) Drugs

DrugCompanyPhase
OATD-02MolecurePhase I
ANXVAnnexin PharmaceuticalsPreclinical
AB821Asher BiotherapeuticsPreclinical
VEGF KinoidNeovacsPreclinical
Undisclosed Preclinical PipelineOncoResponsePreclinical
Undisclosed Platform ProgramDa Zen TheranosticsPre-clinical
Compound42Abbmira TherapeuticsPre-clinical
Clinical Decision Support ServiceCurematchCommercial
CV6-168CV6 TherapeuticsPhase 1a
Chemophototherapy (CPT)POP BiotechnologiesPre-clinical
HRD Testing SolutionSeqOne GenomicsCommercial
Platform Validation & Partnership DevelopmentSingleCell BiotechnologyPre-clinical